Skip to main content
. 2014 Mar 26;16(9):1255–1262. doi: 10.1093/neuonc/nou044

Fig. 4.

Fig. 4.

Overall survival (OS) for recurrent glioblastoma patients (n = 40) who were bevacizumab naïve (n = 14) and those who had failed bevacizumab (n = 26). Median OS for bevacizumab-failed was 18.2 weeks (95% CI, 13.9–27.3 weeks); median OS for bevacizumab-naïve was 62 weeks (95% CI, 26.1 weeks to not reached). P =.001.